{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"39"}]}],"title":"Grade 3 or Higher Decrease in Hemoglobin (mmol/L)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"94"},{"groupId":"OG001","value":"93"}]}],"title":"Grade 3 or Higher Decrease in Leukocytes (10^9/L)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"99"},{"groupId":"OG001","value":"100"}]}],"title":"Grade 3 or Higher Decrease in Lymphocytes (10^9/L)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"92"},{"groupId":"OG001","value":"96"}]}],"title":"Grade 3 or Higher Decrease in Neutrophils (10^9/L)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"32"}]}],"title":"Grade 3 or Higher Decrease in Platelets (10^9/L)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"4"}]}],"title":"Grade 3 or Higher Decrease in Albumin (g/L)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"7"}]}],"title":"Grade 3 or Higher Decrease in Calcium (mmol/L)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}],"title":"Grade 3 or Higher Decrease in Glucose (mmol/L)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}],"title":"Grade 3 or Higher Decrease in Magnesium (mmol/L)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"39"}]}],"title":"Grade 3 or Higher Decrease in Phosphate (mmol/L)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"7"}]}],"title":"Grade 3 or Higher Decrease in Potassium (mmol/L)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"18"}]}],"title":"Grade 3 or Higher Decrease in Sodium (mmol/L)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"124"},{"groupId":"OG001","value":"28"}],"units":"Participants"}],"description":"Percentages were rounded-off.","groups":[{"description":"Participants with r/r B-cell iNHL subtype of FL received the following treatment during the study:\n\n* A conditioning chemotherapy regimen of fludarabine 30 mg/m\\^2/day IV and cyclophosphamide 500 mg/m\\^2/day IV for 3 days (Day -5 to Day -3).\n* A single IV infusion at a target dose of 2×10\\^6 anti-CD19 CAR transduced autologous T cells/kg on Day 0.","id":"OG000","title":"Axicabtagene Ciloleucel (Follicular Lymphoma)"},{"description":"Participants with r/r B-cell iNHL subtype of MZL received the following treatment during the study:\n\n* A conditioning chemotherapy regimen of fludarabine 30 mg/m\\^2/day IV and cyclophosphamide 500 mg/m\\^2/day IV for 3 days (Day -5 to Day -3).\n* A single IV infusion at a target dose of 2×10\\^6 anti-CD19 CAR transduced autologous T cells/kg on Day 0.","id":"OG001","title":"Axicabtagene Ciloleucel (Marginal Zone Lymphoma)"}],"paramType":"NUMBER","populationDescription":"Participants in the Safety Analysis Set were analyzed.","reportingStatus":"POSTED","timeFrame":"Up to 85.6 months","title":"Percentage of Participants With Decrease in Laboratory Values Reported as Grade 3 or Higher","type":"SECONDARY","unitOfMeasure":"percentage of participants"}